The Rate of Insulin use and Suboptimal Glycemic Control among Egyptian Patients with T2DM: Cohort Analysis of Eighth Wave of the International Diabetes Management Practices Study (IDMPS).

IF 2.4 Q3 ENDOCRINOLOGY & METABOLISM
Samir Helmy Assaad Khalil, Mohsen Khaled, Raafat Zakhary, Mark Shereen
{"title":"The Rate of Insulin use and Suboptimal Glycemic Control among Egyptian Patients with T2DM: Cohort Analysis of Eighth Wave of the International Diabetes Management Practices Study (IDMPS).","authors":"Samir Helmy Assaad Khalil, Mohsen Khaled, Raafat Zakhary, Mark Shereen","doi":"10.2174/1573399820666230602100629","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>The International Diabetes Management Practices Study (IDMPS) is an international annual survey aiming to study and characterize the current standards of care for managing DM in developing countries.</p><p><strong>Background: </strong>In Egypt, DM represents a substantial burden on the healthcare system, with an estimated 10.9 million patients, ranking it 10th amongst countries with the highest prevalence of DM. Previous studies showed that to maintain safety and achieve treatment goals among diabetic patients, optimal insulin therapy should be selected individually based on the patient's needs. We reported the proportion of Egyptian T2DM patients on insulin therapy who participated in the eighth wave of the IDMPS.</p><p><strong>Methods: </strong>The 2018 IDMPS wave consisted of cross-sectional and longitudinal phases and aimed to evaluate the proportion of T2DM who were on insulin therapy in 13 countries from four regions. In Egypt, 17 physicians agreed to participate in the present study and were required to include at least one patient.</p><p><strong>Results: </strong>A total of 180 T2DM patients were included in the cross-section phase. At the end of the ninth month of follow-up, data from 170 T2DM patients were available. A total of 39 T2DM patients (21.7%) were on insulin therapy, with a mean duration of 32.4 ± 36.6 months. More than half of the patients (n = 22; 56.4%) were on basal insulin, mainly long-acting (n = 20; 90.9%). The mean basal insulin daily dose was 0.3 ± 0.1 IU/Kg. Notably, 28.2% of the patients received insulin via vials, and 46.2% stated that they were adjusting the insulin dose by themselves. On the other hand, 60.2% of the study population was on oral antidiabetic drugs at the cross-sectional phase. Nearly 17.4% and 27% of the patients in the cross-sectional phase achieved the glycemic target per recommendations of international guidelines and the treating physicians, respectively. At the end of the longitudinal phase, the percentage of T2DM patients who achieved glycemic targets increased to 38.4% and 77.4% as per recommendations of international guidelines and the treating physicians, respectively. Overall, 38.3% of T2DM patients received diabetes education, and 28.9% were involved in an educational program provided by the physician or their clinical staff. Besides, 85.5% of T2DM patients followed their diabetes medication dosage and frequency strictly as prescribed.</p><p><strong>Conclusion: </strong>The proportion of insulin use in patients with T2DM aligned with the previous studies from different countries; however, it is still inadequate to achieve the targeted glycemic control. Nearly one-third of Egyptian patients received diabetes education, highlighting the need for adopting a national educational program. Nonetheless, the level of adherence among T2DM from Egypt appears to be high.</p>","PeriodicalId":10825,"journal":{"name":"Current diabetes reviews","volume":" ","pages":"e020623217590"},"PeriodicalIF":2.4000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10909816/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current diabetes reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1573399820666230602100629","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aims: The International Diabetes Management Practices Study (IDMPS) is an international annual survey aiming to study and characterize the current standards of care for managing DM in developing countries.

Background: In Egypt, DM represents a substantial burden on the healthcare system, with an estimated 10.9 million patients, ranking it 10th amongst countries with the highest prevalence of DM. Previous studies showed that to maintain safety and achieve treatment goals among diabetic patients, optimal insulin therapy should be selected individually based on the patient's needs. We reported the proportion of Egyptian T2DM patients on insulin therapy who participated in the eighth wave of the IDMPS.

Methods: The 2018 IDMPS wave consisted of cross-sectional and longitudinal phases and aimed to evaluate the proportion of T2DM who were on insulin therapy in 13 countries from four regions. In Egypt, 17 physicians agreed to participate in the present study and were required to include at least one patient.

Results: A total of 180 T2DM patients were included in the cross-section phase. At the end of the ninth month of follow-up, data from 170 T2DM patients were available. A total of 39 T2DM patients (21.7%) were on insulin therapy, with a mean duration of 32.4 ± 36.6 months. More than half of the patients (n = 22; 56.4%) were on basal insulin, mainly long-acting (n = 20; 90.9%). The mean basal insulin daily dose was 0.3 ± 0.1 IU/Kg. Notably, 28.2% of the patients received insulin via vials, and 46.2% stated that they were adjusting the insulin dose by themselves. On the other hand, 60.2% of the study population was on oral antidiabetic drugs at the cross-sectional phase. Nearly 17.4% and 27% of the patients in the cross-sectional phase achieved the glycemic target per recommendations of international guidelines and the treating physicians, respectively. At the end of the longitudinal phase, the percentage of T2DM patients who achieved glycemic targets increased to 38.4% and 77.4% as per recommendations of international guidelines and the treating physicians, respectively. Overall, 38.3% of T2DM patients received diabetes education, and 28.9% were involved in an educational program provided by the physician or their clinical staff. Besides, 85.5% of T2DM patients followed their diabetes medication dosage and frequency strictly as prescribed.

Conclusion: The proportion of insulin use in patients with T2DM aligned with the previous studies from different countries; however, it is still inadequate to achieve the targeted glycemic control. Nearly one-third of Egyptian patients received diabetes education, highlighting the need for adopting a national educational program. Nonetheless, the level of adherence among T2DM from Egypt appears to be high.

埃及 T2DM 患者使用胰岛素的比例和血糖控制不理想的情况:第八波国际糖尿病管理实践研究 (IDMPS) 队列分析。
目的:国际糖尿病管理实践研究(IDMPS)是一项国际年度调查,旨在研究和描述发展中国家管理糖尿病的现行医疗标准:背景:在埃及,糖尿病给医疗系统带来了沉重负担,估计有 1090 万患者,在糖尿病发病率最高的国家中排名第 10 位。以往的研究表明,为了保证糖尿病患者的安全并实现治疗目标,应根据患者的需求选择最佳的胰岛素疗法。我们报告了参加第八波IDMPS的埃及T2DM患者接受胰岛素治疗的比例:2018年的IDMPS调查包括横断面和纵断面两个阶段,旨在评估四个地区13个国家的T2DM患者接受胰岛素治疗的比例。在埃及,17 名医生同意参与本研究,并被要求至少纳入一名患者:结果:共有 180 名 T2DM 患者参与了横断面研究。在第九个月的随访结束时,共获得了 170 名 T2DM 患者的数据。共有 39 名 T2DM 患者(21.7%)接受了胰岛素治疗,平均治疗时间为(32.4 ± 36.6)个月。一半以上的患者(22 人;56.4%)使用基础胰岛素,主要是长效胰岛素(20 人;90.9%)。基础胰岛素日平均剂量为 0.3 ±0.1 IU/Kg。值得注意的是,28.2%的患者通过药瓶接受胰岛素,46.2%的患者表示自己正在调整胰岛素剂量。另一方面,60.2% 的研究对象在横断面阶段服用口服抗糖尿病药物。在横断面阶段,分别有近 17.4% 和 27% 的患者达到了国际指南和主治医生建议的血糖目标值。在纵向阶段结束时,根据国际指南和主治医生的建议,达到血糖目标的 T2DM 患者比例分别增至 38.4% 和 77.4%。总体而言,38.3%的T2DM患者接受了糖尿病教育,28.9%的患者参与了由医生或其临床医护人员提供的教育计划。此外,85.5% 的 T2DM 患者严格按照医嘱服用糖尿病药物的剂量和次数:结论:T2DM 患者使用胰岛素的比例与以往不同国家的研究结果一致,但仍不足以实现目标血糖控制。近三分之一的埃及患者接受了糖尿病教育,这说明有必要开展全国性的教育计划。尽管如此,埃及 T2DM 患者的依从性似乎很高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current diabetes reviews
Current diabetes reviews ENDOCRINOLOGY & METABOLISM-
CiteScore
6.30
自引率
0.00%
发文量
158
期刊介绍: Current Diabetes Reviews publishes frontier reviews on all the latest advances on diabetes and its related areas e.g. pharmacology, pathogenesis, complications, epidemiology, clinical care, and therapy. The journal"s aim is to publish the highest quality review articles dedicated to clinical research in the field. The journal is essential reading for all researchers and clinicians who are involved in the field of diabetes.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信